1. Clinical & Scientific Overview
Trastuzumab (TIP-MED-000576, Reference Code [ONC-27]) is classified under
Oncology & Antineoplastic Medicines as a Monoclonal Antibody (Anti-HER2 Targeted Biologic) • Humanised Anti-HER2 (ErbB2) IgG1 Monoclonal Antibody.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Herceptin / Biceltis (Roche Products India), CANMAb (Biocon), Hertraz (Mylan / Viatris)
Lyophilised Powder for IV Infusion: 150 mg vial, 440 mg multi-dose vial
Oncology Specialisation & Cytotoxic Safety Protocol
Monoclonal Antibody (Anti-HER2 Targeted Biologic)
Antineoplastic Biologic
Standard Regimen & Cycle Context: 3-Weekly Regimen: 8 mg/kg IV loading dose over 90 min, then 6 mg/kg IV over 30–90 min every 21 days (for 1 year / 18 cycles in adjuvant breast cancer).
Signature Dose-Limiting Toxicities & Organ Monitoring: Reversible Type II Cardiomyopathy / LVEF decline (risk increases from 3–7% with trastuzumab alone to 27% if given concurrently with doxorubicin — therefore give sequentially after anthracyclines, never concurrently!), first-infusion chills/fever, and oligohydramnios if used in pregnancy.
Extravasation, Premedication & Safe Cytotoxic Handling: PHARMACEUTICAL DILUTION RULE: Dilute Trastuzumab STRICTLY in 0.9% Sodium Chloride (NEVER dilute in 5% Dextrose / D5W, which causes protein aggregation!); NEVER substitute mg-for-mg with Ado-Trastuzumab Emtansine (Kadcyla / T-DM1) or Trastuzumab Deruxtecan (Enhertu); monitor LVEF every 3 months.
3. Mechanism of Action & Pharmacodynamics
Binds subdomain IV of the extracellular domain of the HER2 (ERBB2) receptor tyrosine kinase, inhibiting PI3K/AKT/mTOR survival signalling, preventing HER2 extracellular domain shedding, and recruiting NK cells for ADCC.
4. Therapeutic Indications & Evidence-Supported Uses
- HER2-positive (IHC 3+ or FISH amplified) Early and Metastatic Breast Cancer
- HER2-positive Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 3-Weekly Regimen: 8 mg/kg IV loading dose over 90 min, then 6 mg/kg IV over 30–90 min every 21 days (for 1 year / 18 cycles in adjuvant breast cancer).
Administration & Meal Timing: 3-Weekly Regimen: 8 mg/kg IV loading dose over 90 min, then 6 mg/kg IV over 30–90 min every 21 days (for 1 year / 18 cycles in adjuvant breast cancer).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Trastuzumab or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Reversible Type II Cardiomyopathy / LVEF decline (risk increases from 3–7% with trastuzumab alone to 27% if given concurrently with doxorubicin — therefore give sequentially after anthracyclines, never concurrently!), first-infusion chills/fever, and oligohydramnios if used in pregnancy.
8. Adverse Effects Profile
- Reversible Type II Cardiomyopathy / LVEF decline (risk increases from 3–7% with trastuzumab alone to 27% if given concurrently with doxorubicin — therefore give sequentially after anthracyclines, never concurrently!), first-infusion chills/fever, and oligohydramnios if used in pregnancy.
- Reversible Type II Cardiomyopathy / LVEF decline (risk increases from 3–7% with trastuzumab alone to 27% if given concurrently with doxorubicin — therefore give sequentially after anthracyclines, never concurrently!), first-infusion chills/fever, and oligohydramnios if used in pregnancy.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Reversible Type II Cardiomyopathy / LVEF decline (risk increases from 3–7% with trastuzumab alone to 27% if given concurrently with doxorubicin — therefore give sequentially after anthracyclines, never concurrently!), first-infusion chills/fever, and oligohydramnios if used in pregnancy.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: PHARMACEUTICAL DILUTION RULE: Dilute Trastuzumab STRICTLY in 0.9% Sodium Chloride (NEVER dilute in 5% Dextrose / D5W, which causes protein aggregation!); NEVER substitute mg-for-mg with Ado-Trastuzumab Emtansine (Kadcyla / T-DM1) or Trastuzumab Deruxtecan (Enhertu); monitor LVEF every 3 months.
Pharmacist Patient Counselling Points:
- PHARMACEUTICAL DILUTION RULE: Dilute Trastuzumab STRICTLY in 0.9% Sodium Chloride (NEVER dilute in 5% Dextrose / D5W, which causes protein aggregation!); NEVER substitute mg-for-mg with Ado-Trastuzumab Emtansine (Kadcyla / T-DM1) or Trastuzumab Deruxtecan (Enhertu); monitor LVEF every 3 months.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: PHARMACEUTICAL DILUTION RULE: Dilute Trastuzumab STRICTLY in 0.9% Sodium Chloride (NEVER dilute in 5% Dextrose / D5W, which causes protein aggregation!); NEVER substitute mg-for-mg with Ado-Trastuzumab Emtansine (Kadcyla / T-DM1) or Trastuzumab Deruxtecan (Enhertu); monitor LVEF every 3 months.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.